The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.
作者信息
Rousseau Benoit, Foote Michael B, Maron Steven B, Diplas Bill H, Lu Steve, Argilés Guillem, Cercek Andrea, Diaz Luis A
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY.
Johns Hopkins Medical Institutes, Baltimore, MD.
出版信息
N Engl J Med. 2021 Mar 25;384(12):1168-1170. doi: 10.1056/NEJMc2031965.
Abstract
摘要
相似文献
1
The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.
N Engl J Med. 2021 Mar 25;384(12):1168-1170. doi: 10.1056/NEJMc2031965.
2
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
3
Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.
Clin Colorectal Cancer. 2019 Dec;18(4):307-309. doi: 10.1016/j.clcc.2019.08.001. Epub 2019 Sep 4.
4
Mismatch repair deficiency predicts benefit of anti-PD-1 therapy.
Lancet Oncol. 2015 Jul;16(7):e319. doi: 10.1016/S1470-2045(15)00031-5. Epub 2015 Jun 7.
5
Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
Trends Cancer. 2017 Oct;3(10):675-677. doi: 10.1016/j.trecan.2017.08.002. Epub 2017 Sep 4.
6
Hypermutated Tumors and Immune Checkpoint Inhibition.
Drugs. 2018 Feb;78(2):155-162. doi: 10.1007/s40265-018-0863-0.
7
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
8
Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
J Hematol Oncol. 2015 Nov 5;8:124. doi: 10.1186/s13045-015-0222-5.
9
Immunotherapy in colorectal cancer with mismatch repair deficiency.
Clin Adv Hematol Oncol. 2019 May;17(5):265-267.
10
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
引用本文的文献
1
Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden.
Cancers (Basel). 2025 Aug 16;17(16):2673. doi: 10.3390/cancers17162673.
2
Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer.
iScience. 2025 Jun 2;28(9):112804. doi: 10.1016/j.isci.2025.112804. eCollection 2025 Sep 19.
3
Therapeutic targeting of mismatch repair-deficient cancers.
Nat Rev Clin Oncol. 2025 Jul 10. doi: 10.1038/s41571-025-01054-6.
4
Role of tumor mutational burden in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Front Immunol. 2025 May 26;16:1592761. doi: 10.3389/fimmu.2025.1592761. eCollection 2025.
5
Optimising Cancer Medicine in Clinical Practices: Are Neoadjuvant and Adjuvant Immunotherapies Affordable for Cancer Patients in Low- and Middle-Income Countries?
Cancers (Basel). 2025 May 21;17(10):1722. doi: 10.3390/cancers17101722.
6
[Chemotherapy, targeted therapy and immunotherapy of metastatic colorectal cancer : What is new?].
Radiologie (Heidelb). 2025 Apr 24. doi: 10.1007/s00117-025-01455-9.
7
Enhancing immunotherapy with tumour-responsive nanomaterials.
Nat Rev Clin Oncol. 2025 Apr;22(4):262-282. doi: 10.1038/s41571-025-01000-6. Epub 2025 Mar 6.
8
Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer.
bioRxiv. 2025 Feb 17:2025.02.12.637954. doi: 10.1101/2025.02.12.637954.
9
Current and future perspectives in the management and treatment of colorectal cancer.
World J Clin Oncol. 2025 Feb 24;16(2):100807. doi: 10.5306/wjco.v16.i2.100807.
10
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial.
Nat Commun. 2025 Feb 24;16(1):1932. doi: 10.1038/s41467-025-57184-z.
本文引用的文献
1
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
2
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.
3
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
Zotero 插件